17 June 2026
17 June 2026
Article doesn't exist
Pharma is employing AI to support approval submissions by predicting how regulators will react before data is submitted.
Completion of the transaction is expected in the fourth quarter of 2026.
SpliSense is currently conducting a Phase IIb trial with its antisense oligonucleotide therapy.
The COMP noted early clinical data indicate Zoci may demonstrate a more favourable effect than existing authorised therapies.
The expanded licensing lets AviadoBio pursue partnerships for broader applications, including cardiovascular, nephrology, oncology, and beyond the CNS.
New data for Talvey and Tecvayli was presented at the annual meeting as J&J directs its therapies in earlier-line settings.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
